Global AI firm Innoplexus launched an innovative blockchain platform to dramatically raise the amount of data available for drug research and discovery. This new platform, an update to Innoplexus' flagship...
Read More
Gunjan Bhardwaj helps pharmaceutical companies to find out more about diseases. By harnessing artificial intelligence, pharmaceutical companies are able to develop drugs more quickly. Frankfurt. It was a life-changing experience for...
Read More
Local pharmaceutical firms should brace for a new era where drugmakers take advantage of artificial intelligence (AI) to develop a new medicine, experts said. The AI-using new drug development has already...
Read More
Indian and Swabian Together with friends from India, Gunjan Bhardwaj has successfully launched Innoplexus, a sophisticated ecosystem of continuous analytics, powered by artificial intelligence and machine learning.The goal: Innoplexus wants to...
Read More
Dr. Gunjan Bhardwaj is the founder and CEO of Innoplexus AG. With the help of artificial intelligence, blockchain and big data analysis applications, its iPlexus software has crawled over 300...
Read More
With a dramatic rise in physician burnout and many physicians exiting the field prematurely, the health care industry is looking to artificial intelligence (AI) to provide much needed support. AI can...
Read More
It’s no surprise that the public hates Big Pharma. They rank just under the government on most Americans’ despised institution list. ...
Read More
Innoplexus is at the forefront of decision-making technology as the company works in data aggregation to provide to...
Read More
We are in the midst of a significant shift in pharmaceutical drug development, with many leading companies focusing increasingly on orphan drugs targeted at small niche markets. An orphan disease is...
Read More
Companies that thrive on sustaining products over a long period are always at risk of classic disruptive innovation—losing business to a smaller company with fewer resources that jumps in, improves...
Read More
